Market Overview:
The global multiple myeloma drugs market reached a value of US$ 19.7 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 28.1 Billion by 2027, exhibiting a CAGR of 6.6% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.
Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body’s immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple myeloma drugs market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on therapy, drug type, end-user and distribution channel.
Breakup by Therapy:
- Targeted Therapy
- Biologic Therapy
- Chemotherapy
- Others
Breakup by Drug Type:
- Immunomodulatory Drugs
- Proteasome Inhibitors
- Histone Deacetylase Inhibitors
- Monoclonal Antibody Drugs
- Steroids
- Others
Breakup by End-User:
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Breakup by Region:
- North America
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., etc.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Therapy, Drug Type, End-User, Distribution Channel, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Amgen Inc., Bristol Myers Squibb, Daiichi Sankyo Co., Ltd., Sanofi-Aventis Groupe (Genzyme Corporation), Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., PHARMA MAR, S.A., Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What has been the impact of COVID-19 on the global multiple myeloma drugs market?
- What is the breakup of the market based on the therapy?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the end-user?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global multiple myeloma drugs market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Multiple Myeloma Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Therapy
6.1 Targeted Therapy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biologic Therapy
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Chemotherapy
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Drug Type
7.1 Immunomodulatory Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Proteasome Inhibitors
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Histone Deacetylase Inhibitors
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Monoclonal Antibody Drugs
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Steroids
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast
8 Market Breakup by End-User
8.1 Men
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Women
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Indicators
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Amgen Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bristol Myers Squibb
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Daiichi Sankyo Co.
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 Johnson & Johnson Services, Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Merck & Co., Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Novartis International AG
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 PHARMA MAR, S.A.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.10 Takeda Pharmaceutical Company Limited.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Teva Pharmaceutical Industries Ltd.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
List of Figures
Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2021
Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2021
Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2021
Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2021
Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2021
Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2016 & 2021
Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 89: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
Figure 90: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
Figure 91: Global: Multiple Myeloma Drugs Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2022-2027
Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2022-2027
Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2022-2027
Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2022-2027
Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Multiple Myeloma Drugs Market Structure
Table 8: Global: Multiple Myeloma Drugs Market: Key Players